68
688108.SHG Sino Medical Sciences Technology In
- Market cap
- CNY 5.93B
- P/E
- 61.7x
- P/B
- 5.22x
- ROE
- 9.1%
- Dividend yield
- 0.07%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688108.SHG undervalued?
Graham numberThe Graham number of Sino Medical Sciences Technology In cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sino Medical Sciences Technology In fundamental analysis
No fundamental analysis for Sino Medical Sciences Technology In yet.
Sino Medical Sciences Technology In stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sino Medical Sciences Technology In
Sino Medical Sciences Technology Inc., a medical device company, engages in the research, development, production, and distribution of interventional medical devices in China. Its products include coronary drug stents, coronary balloons catheter, intracranial rapid exchange balloons, and intracranial drug-eluting stents, as well as transapical mitral valve replacement system. Sino Medical Sciences Technology Inc. was incorporated in 2007 and is headquartered in Tianjin, Chin…
Full company profileSino Medical Sciences Technology In financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sino Medical Sciences Technology In annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 266M | 322M | 380M | 436M | 327M | 194M | 193M | 343M | 459M | 525M | 600M |
| Gross Profit | 227M | 269M | 312M | 361M | 260M | 134M | 107M | 198M | 266M | 525M | 421M |
| Operating Income | 38.0M | 82.3M | 108M | 109M | 24.0M | -163M | -219M | -69.4M | -17.0M | 66.8M | 136M |
| EBITDA | 55.8M | 97.7M | 124M | 136M | 67.3M | -108M | -168M | -13.0M | 53.3M | 133M | 128M |
| Net Income | 28.7M | 66.1M | 89.2M | 90.0M | 22.5M | -131M | -162M | -39.6M | 1.50M | 47.3M | 92.2M |
| EPS | 0.14 | 0.25 | 0.25 | 0.24 | 0.05 | -0.32 | -0.40 | -0.10 | 0.00 | 0.11 | 0.22 |
| Balance Sheet | |||||||||||
| Total Assets | 281M | 710M | 806M | 1.21B | 1.22B | 1.10B | 1.07B | 1.19B | 1.30B | 1.35B | 1.38B |
| Total Liabilities | 78.1M | 104M | 105M | 107M | 140M | 158M | 180M | 324M | 402M | -932M | 289M |
| Shareholders' Equity | 203M | 607M | 701M | 1.10B | 1.08B | 928M | 847M | 820M | 867M | 932M | 1.02B |
| Cash & Short-term Investments | 43.7M | 107M | 375M | 638M | 545M | 288M | 203M | 189M | 292M | 358M | 473M |
| Total Debt | 1.03M | 1.17M | 955K | - | 50.9M | 44.3M | 58.3M | 144M | 127M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 42.2M | 70.3M | 97.6M | 138M | 70.5M | -60.1M | -111M | 56.8M | 131M | 162M | - |
| Capital Expenditure | 44.3M | 76.3M | 98.9M | 180M | 113M | 158M | 111M | 67.7M | 70.0M | 45.8M | 19.8M |
| Free Cash Flow | -2.08M | -5.93M | -1.31M | -42.4M | -42.3M | -219M | -222M | -10.8M | 61.2M | 116M | 172M |
| Ratios | |||||||||||
| ROE | 14.1% | 10.9% | 12.7% | 8.2% | 2.1% | -14.1% | -19.2% | -4.8% | 0.2% | 5.1% | 9.1% |
| ROA | 10.2% | 9.3% | 11.1% | 7.5% | 1.8% | -11.9% | -15.2% | -3.3% | 0.1% | 3.5% | 6.7% |
| Net Profit Margin | 10.8% | 20.5% | 23.4% | 20.7% | 6.9% | -67.3% | -84.2% | -11.5% | 0.3% | 9.0% | 15.4% |
| Debt to Equity | 0.01x | 0.00x | 0.00x | - | 0.05x | 0.05x | 0.07x | 0.18x | 0.15x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sino Medical Sciences Technology In dividends
- Dividend yield
- 0.07%
- Forward dividend
- -
- Payout ratio
- 8.9%
- Ex-dividend date
- Jul 10, 2020
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 4.19M | 0.01 | 8.9% |
| 2024 | CNY 4.11M | 0.01 | 274.4% |
| 2023 | CNY 2.01M | 0.01 | - |
| 2022 | CNY 940K | 0.00 | - |
| 2021 | CNY 29.4K | 0.00 | - |
| 2020 | CNY 41.0M | 0.10 | 182.3% |
| 2019 | CNY 41.3M | 0.11 | 45.9% |
| 2018 | CNY 41.3M | 0.12 | 46.3% |
| 2017 | CNY 9.00M | 0.03 | 13.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Sino Medical Sciences Technology In
- Insiders 26.09%
- Institutions 4.14%
- Public & others 69.77%
- Shares outstanding 418M
- Free float 265M
Sino Medical Sciences Technology In company profile
- Company name
- Sino Medical Sciences Technology In
- Ticker
- 688108.SHG
- ISIN
- CNE100003NY2
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 649
- Fiscal year end
- December
- Address
- TEDA Biomedical R&D Building, Tianjin, China, 300457
- Phone
- 86 22 5986 2900
- Website
- sinomed.com
About Sino Medical Sciences Technology In
Sino Medical Sciences Technology Inc., a medical device company, engages in the research, development, production, and distribution of interventional medical devices in China. Its products include coronary drug stents, coronary balloons catheter, intracranial rapid exchange balloons, and intracranial drug-eluting stents, as well as transapical mitral valve replacement system. Sino Medical Sciences Technology Inc. was incorporated in 2007 and is headquartered in Tianjin, China.
Sino Medical Sciences Technology In management
8- Mr. Jianhua SunChairman & GM · born 1961
- Ms. Lihua ShenCFO & Accounting Supervisor · born 1971
- Mr. Liye CuiDeputy General Manager of Production & Operation · born 1974
- Ms. Lin ChenDirector of Human Resources & Employee Director · born 1982
- Mr. Xiaoran KangDeputy GM & Director · born 1986
- Mr. Kai HuangBoard Secretary & Director · born 1973
- Mr. Wenbin CaiR&D Director · born 1984
- Mr. Tianzhu LiCore Technical Personnel · born 1983